Effective suppression of inflammation with tumor necrosis factor inhibitor therapy decreases radiographic progression in early ankylosing spondylitis.
Researchers observed increased rates of both knee and hip arthroplasties in older patients with ankylosing spondylitis.
Reduced cardiorespiratory fitness may be associated with increased risk for CVD in ankylosing spondylitis.
Treatment with risankizumab was not effective in reducing the signs and symptoms of ankylosing spondylitis at 12 weeks.
Data strengthen the indication for performing a thorough CVD risk assessment in patients with inflammatory disorders.
Fatigue had a significant and independent effect on work disability measures in rheumatoid arthritis and ankylosing spondylitis.
Axial Psoriatic Arthritis and Ankylosing Spondylitis: Comparing Clinical, Radiologic CharacteristicsJune 20, 2018
It is unclear whether ankylosing spondylitis and axial psoriatic arthritis are part of a spectrum of the same disease, or whether they are separate diseases with overlapping features.
Dose-related use of NSAIDs together with TNFi in patients with ankylosing spondylitis has a synergistic effect in slowing radiographic progression.
Researchers used data from social media to identify concerns and perceptions regarding biologic therapies.
Researchers assessed achievement of minimally important changes in SPARCC scores in biologic-naive patients with ankylosing spondylitis treated with tofacitinib or placebo.
A number of factors that include age, the presence of enthesitis, and depressive symptoms may be associated with neuropathic pain in ankylosing spondylitis.
Researchers sought to provide information on pregnancy outcomes, including major congenital malformations and other maternal and fetal adverse outcomes, in women treated with certolizumab pegol.
Nonmandatory transitioning from originator etanercept to biosimilar etanercept SB4 using a specifically designed communication strategy showed a slightly lower persistence rate and smaller decreases in disease activity.
TNFi therapy yielded favorable results in patients with AS or PsA, with progressively better responses between 4 months and 3 years.
The FDA has approved a label update to include pharmacokinetic data showing low transfer of certolizumab pegol through placenta and minimal transfer to breast milk from mother to infant.
Investigators evaluated sex differences in the effectiveness of tumor necrosis factor inhibitors in patients with ankylosing spondylitis.
The risk for aortic regurgitation and cardiac rhythm abnormalities was evaluated in a nationwide cohort of patients with spondyloarthritis.
Decreases in spinal and sacroiliac joint inflammation on MRI were maintained through 204 weeks with certolizumab pegol treatment.
Spinal fracture-free survival among patients with AS was not significantly affected by the use of bDMARD therapy.
Investigators examined the long-term safety and efficacy of a subcutaneous maintenance dose of secukinumab 150 and 300 mg.
Male gender and the Charlson Comorbidity Index score contributed significantly to fracture risk in this population.
Research suggests that the best site to assess bone loss in patients with ankylosing spondylitis is the femoral neck.
Low-dose computed tomography detects more bone proliferation in patients with ankylosing spondylitis compared with conventional radiography.
Transitioning from an originator agent to its biosimilar has the potential to reduce healthcare costs without compromising outcomes.
The use of tumor necrosis factor inhibitors to modify structural changes in axial spondyloarthritis may prevent progression to spinal disease.
Although the effect of antirheumatic drugs on inflammatory arthritic conditions has not been fully elucidated, treatment with methotrexate and tumor necrosis factor inhibitors has been found to improve endothelial dysfunction in this population.
The SSDM series of applications is cost-effective for patients of rheumatologists.
Investigators sought to determine the long-term safety of adalimumab use in patients with arthritis and other immune-related diseases.
Predictors of subclinical accelerated atherosclerosis were examined in a recent study of patients with spondyloarthritis without overt cardiovascular disease.
The first lactation study of its kind evaluated whether a biologic drug is transferred into mature breast milk
Rheumatology Advisor Articles
- Efficacy of ABT-122 Maintained in Psoriatic Arthritis, Rheumatoid Arthritis at 36 Weeks
- Comorbid Fibromyalgia Influences Disease Activity, Quality of Life in Axial Spondyloarthritis
- Knee Load Associated With Increased Walking Pain in Osteoarthritis
- Pain Catastrophizing Decreases in Rheumatoid Arthritis After DMARD Initiation
- CVD Prevention Measures Inadequate in Patients With Inflammatory Joint Diseases
- Genetic Screening May Predict Osteoporosis, Fracture Risk
- Exploring the Clinical Implications of Cannabinoid Use in Rheumatoid Arthritis
- Diagnosing Lyme Disease in Children With Neuropsychiatric Illness
- Predicting Primary Nonresponse to Methotrexate in Rheumatoid Arthritis
- Prednisone, Prednisolone Does Not Adversely Affect Bone Mineral Density in RA
- Sulfasalazine Reduces Pneumocystis Pneumonia Risk in Rheumatoid Arthritis
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Response to Certolizumab Pegol at 12 Weeks Predicts Long-Term RA Outcomes
- Performance Phenotypes of Lumbar Spinal Stenosis and OA With Accelerometry Data
- Characteristics of Early-Onset SLE Distinguished From Mimicking Conditions